Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
the Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
Laryngoscope. 2020 Apr;130(4):E140-E143. doi: 10.1002/lary.28038. Epub 2019 May 10.
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020.
派姆单抗，一种抗 PD-1 检查点抑制剂，用于接受过铂类方案治疗后复发或转移性头颈部鳞状细胞癌的患者。作为单药治疗，其通常具有良好的耐受性，但一小部分患者可能会发生免疫介导的炎症反应。我们报告了一例接受派姆单抗治疗的患者出现黏膜炎和喉水肿，并复习了文献。《喉镜》，130：E140-E143，2020。
